Trials / Withdrawn
WithdrawnNCT04100330
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 2, Randomized, Open-Label, Multicenter Study of Ficlatuzumab in Combination With High-Dose Cytarabine (HiDAC) and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AVEO Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in subjects with relapsed or refractory acute myeloid leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ficlatuzumab | Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor. |
| DRUG | Cytarabine | Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells. |
Timeline
- Start date
- 2020-01-31
- Primary completion
- 2020-03-27
- Completion
- 2020-03-27
- First posted
- 2019-09-24
- Last updated
- 2020-03-31
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04100330. Inclusion in this directory is not an endorsement.